CA2615372A1 - Influenza virus-like particles (vlps) comprising hemagglutinin - Google Patents

Influenza virus-like particles (vlps) comprising hemagglutinin Download PDF

Info

Publication number
CA2615372A1
CA2615372A1 CA002615372A CA2615372A CA2615372A1 CA 2615372 A1 CA2615372 A1 CA 2615372A1 CA 002615372 A CA002615372 A CA 002615372A CA 2615372 A CA2615372 A CA 2615372A CA 2615372 A1 CA2615372 A1 CA 2615372A1
Authority
CA
Canada
Prior art keywords
plant
influenza
virus
vlps
vlp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002615372A
Other languages
English (en)
French (fr)
Inventor
Marc-Andre D'aoust
Manon Couture
Frederic Ors
Sonia Trepanier
Pierre-Olivier Lavoie
Michele Dargis
Louis-Philippe Vezina
Nathalie Landry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicago Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to SI200831024T priority Critical patent/SI2173886T1/sl
Priority to CA2693956A priority patent/CA2693956C/en
Priority to EA201000195A priority patent/EA018206B1/ru
Priority to US12/669,033 priority patent/US20100239610A1/en
Priority to CN2008801070729A priority patent/CN101883856B/zh
Priority to ES08783201T priority patent/ES2428384T3/es
Priority to NZ582360A priority patent/NZ582360A/en
Priority to PT87832010T priority patent/PT2173886E/pt
Priority to EP08783201.0A priority patent/EP2173886B1/en
Priority to PL08783201T priority patent/PL2173886T3/pl
Priority to DK08783201.0T priority patent/DK2173886T3/da
Priority to PCT/CA2008/001281 priority patent/WO2009009876A1/en
Priority to MYPI2010000142A priority patent/MY155236A/en
Priority to BRPI0813724-2A priority patent/BRPI0813724B1/pt
Priority to KR1020107002538A priority patent/KR101541330B1/ko
Priority to AU2008278222A priority patent/AU2008278222B2/en
Priority to MX2010000525A priority patent/MX2010000525A/es
Priority to HK10109048.1A priority patent/HK1142627B/en
Priority to JP2010516334A priority patent/JP5624465B2/ja
Priority to DK12183854.4T priority patent/DK2610345T3/en
Priority to BRPI0906960-7A priority patent/BRPI0906960B1/pt
Priority to JP2010542486A priority patent/JP2011509661A/ja
Priority to SG2013004577A priority patent/SG187500A1/en
Priority to EP12183854.4A priority patent/EP2610345B1/en
Priority to NZ587108A priority patent/NZ587108A/xx
Priority to AU2009202819A priority patent/AU2009202819B2/en
Priority to PCT/CA2009/000032 priority patent/WO2009076778A1/en
Priority to EP09700061A priority patent/EP2238253B1/en
Priority to MX2010007962A priority patent/MX2010007962A/es
Priority to ES12183854.4T priority patent/ES2554703T3/es
Priority to KR1020107018343A priority patent/KR20100120157A/ko
Priority to PT121838544T priority patent/PT2610345E/pt
Priority to EA201001198A priority patent/EA034733B1/ru
Priority to CN201310021693.8A priority patent/CN103122354B/zh
Priority to CA2707235A priority patent/CA2707235C/en
Priority to US12/863,772 priority patent/US20100310604A1/en
Priority to CN2009801097815A priority patent/CN101978066A/zh
Priority to KR1020167010959A priority patent/KR101956910B1/ko
Publication of CA2615372A1 publication Critical patent/CA2615372A1/en
Priority to US13/003,570 priority patent/US9492528B2/en
Priority to IL203018A priority patent/IL203018A/en
Priority to CR11209A priority patent/CR11209A/es
Priority to IS8874A priority patent/IS2920B/is
Priority to MA32604A priority patent/MA31681B1/fr
Priority to ZA2010/00972A priority patent/ZA201000972B/en
Priority to IL206967A priority patent/IL206967A/en
Priority to CR11612A priority patent/CR11612A/es
Priority to IS8919A priority patent/IS2982B/is
Priority to MA33088A priority patent/MA32439B1/fr
Priority to ZA2010/05917A priority patent/ZA201005917B/en
Priority to US13/734,886 priority patent/US9452210B2/en
Priority to US13/748,531 priority patent/US9458470B2/en
Priority to HK13113472.5A priority patent/HK1186207B/en
Priority to IL230708A priority patent/IL230708A/en
Priority to JP2014039035A priority patent/JP5990207B2/ja
Priority to JP2015231583A priority patent/JP2016032477A/ja
Priority to US15/256,119 priority patent/US10190132B2/en
Priority to US16/219,306 priority patent/US11434497B2/en
Priority to US17/815,503 priority patent/US20230044454A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/04—Intramolecular oxidoreductases (5.3) transposing S-S bonds (5.3.4)
    • C12Y503/04001—Protein disulfide-isomerase (5.3.4.1), i.e. disufide bond-forming enzyme
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F9/00—Arrangements for program control, e.g. control units
    • G06F9/06—Arrangements for program control, e.g. control units using stored programs, i.e. using an internal store of processing equipment to receive or retain programs
    • G06F9/46—Multiprogramming arrangements
    • G06F9/50—Allocation of resources, e.g. of the central processing unit [CPU]
    • G06F9/5005—Allocation of resources, e.g. of the central processing unit [CPU] to service a request
    • G06F9/5027—Allocation of resources, e.g. of the central processing unit [CPU] to service a request the resource being a machine, e.g. CPUs, Servers, Terminals
    • G06F9/505—Allocation of resources, e.g. of the central processing unit [CPU] to service a request the resource being a machine, e.g. CPUs, Servers, Terminals considering the load
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/517—Plant cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16223—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F2209/00—Indexing scheme relating to G06F9/00
    • G06F2209/50—Indexing scheme relating to G06F9/50
    • G06F2209/508—Monitor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Software Systems (AREA)
  • Theoretical Computer Science (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
CA002615372A 2007-07-13 2008-01-21 Influenza virus-like particles (vlps) comprising hemagglutinin Abandoned CA2615372A1 (en)

Priority Applications (58)

Application Number Priority Date Filing Date Title
SI200831024T SI2173886T1 (sl) 2007-07-13 2008-07-11 Delci podobni virusu gripe (VLPs), ki vsebujejo v rastlini proizveden hemagglutin
CA2693956A CA2693956C (en) 2007-07-13 2008-07-11 Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant
EA201000195A EA018206B1 (ru) 2007-07-13 2008-07-11 Вирусоподобные частицы вируса гриппа, включающие гемагглютинин, продуцированный в растении
US12/669,033 US20100239610A1 (en) 2007-07-13 2008-07-11 Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant
CN2008801070729A CN101883856B (zh) 2007-07-13 2008-07-11 包含植物内生产之血凝素的流感病毒样颗粒(vlp)
ES08783201T ES2428384T3 (es) 2007-07-13 2008-07-11 Partículas similares al virus de la influenza (VLP) que contienen hemaglutinina producida dentro de una planta
NZ582360A NZ582360A (en) 2007-07-13 2008-07-11 Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant
PT87832010T PT2173886E (pt) 2007-07-13 2008-07-11 Partículas semelhantes ao vírus da gripe (vlps) compreendendo hemaglutinina produzida numa planta
EP08783201.0A EP2173886B1 (en) 2007-07-13 2008-07-11 Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant
PL08783201T PL2173886T3 (pl) 2007-07-13 2008-07-11 Cząstki wirusopodobne (VLP) obejmujące hemaglutyninę wytworzoną w roślinie
DK08783201.0T DK2173886T3 (da) 2007-07-13 2008-07-11 Influenzaviruslignende partikler (VLPS) omfattende hæmagglutinin produceret i en plante
PCT/CA2008/001281 WO2009009876A1 (en) 2007-07-13 2008-07-11 Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant
MYPI2010000142A MY155236A (en) 2007-07-13 2008-07-11 Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant
BRPI0813724-2A BRPI0813724B1 (pt) 2007-07-13 2008-07-11 Método de produção de partículas similares ao vírus influenza (vlps) em uma planta, partículas similares a vírus (vlps) e composição
KR1020107002538A KR101541330B1 (ko) 2007-07-13 2008-07-11 식물에서 생산된 헤마글루티닌을 포함하는 인플루엔자 바이러스-유사 입자(ＶＬＰｓ)
AU2008278222A AU2008278222B2 (en) 2007-07-13 2008-07-11 Influenza virus-like particles (VLPs) comprising hemagglutinin produced within a plant
MX2010000525A MX2010000525A (es) 2007-07-13 2008-07-11 Particulas similares al virus de la influenza (vlps) que comprenden hemaglutinina producida dentro de una planta.
HK10109048.1A HK1142627B (en) 2007-07-13 2008-07-11 Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant
JP2010516334A JP5624465B2 (ja) 2007-07-13 2008-07-11 植物内で生成されるヘマグルチニンを含むインフルエンザウイルス様粒子（ｖｌｐ）
DK12183854.4T DK2610345T3 (en) 2007-11-27 2009-01-12 RECOMBINANT INFLUENZA VIRUS SIMULAR PARTICULARS (VLPS) MADE IN TRANSGENE PLANTS THAT EXPRESS HEMAGGLUTININ
BRPI0906960-7A BRPI0906960B1 (pt) 2008-01-21 2009-01-12 Ácido nucleico compreendendo uma sequência de nucleotídeos codificando uma hemaglutinina do vírus de influenza (ha), partículas semelhantes a vírus (vlps), seu método de produção, composição e uso dos mesmos
JP2010542486A JP2011509661A (ja) 2007-11-27 2009-01-12 ヘマグルチニンを発現するトランスジェニック植物において産生された組換え型インフルエンザウイルス様粒子（ｖｌｐ）
SG2013004577A SG187500A1 (en) 2008-01-21 2009-01-12 Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
EP12183854.4A EP2610345B1 (en) 2007-11-27 2009-01-12 Recombinant influenza virus-like particles (VLPS) produced in transgenic plants expressing hemagglutinin
NZ587108A NZ587108A (en) 2007-11-27 2009-01-12 Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
AU2009202819A AU2009202819B2 (en) 2007-07-13 2009-01-12 Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin
PCT/CA2009/000032 WO2009076778A1 (en) 2007-11-27 2009-01-12 Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
EP09700061A EP2238253B1 (en) 2007-11-27 2009-01-12 Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
MX2010007962A MX2010007962A (es) 2007-11-27 2009-01-12 Particulas tipo virus de influenza recombinante (vlp) producidas en plantas transgenicas que expresan hemaglutinina.
ES12183854.4T ES2554703T3 (es) 2007-11-27 2009-01-12 Partículas recombinantes semejantes al virus de la influenza (VLP) producidas en plantas transgénicas que expresan hemaglutinina
KR1020107018343A KR20100120157A (ko) 2007-11-27 2009-01-12 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(ＶＬＰｓ)
PT121838544T PT2610345E (pt) 2007-11-27 2009-01-12 Partículas semelhantes ao vírus (vlps) da gripe recombinantes produzidas em plantas transgénicas que expressam hemaglutinina
EA201001198A EA034733B1 (ru) 2008-01-21 2009-01-12 Нуклеиновая кислота для увеличенной экспрессии гемагглютинина вируса гриппа в растении и ее применение
CN201310021693.8A CN103122354B (zh) 2007-11-27 2009-01-12 表达血凝素之转基因植物中生产的重组流感病毒样颗粒(vlp)
CA2707235A CA2707235C (en) 2007-11-27 2009-01-12 Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
US12/863,772 US20100310604A1 (en) 2007-11-27 2009-01-12 Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
CN2009801097815A CN101978066A (zh) 2007-11-27 2009-01-12 表达血凝素之转基因植物中生产的重组流感病毒样颗粒(vlp)
KR1020167010959A KR101956910B1 (ko) 2008-01-21 2009-01-12 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(ＶＬＰｓ)
US13/003,570 US9492528B2 (en) 2007-07-13 2009-07-02 Influenza virus-like particles (VLPS) comprising hemagglutinin
IL203018A IL203018A (en) 2007-07-13 2009-12-29 Influenza virus-like particles containing megalotinin produced in a plant
CR11209A CR11209A (es) 2007-07-13 2010-01-11 Particulas similares al virus de la influenza (vlps) que comprenden hemaglutinina producida dentro de una planta
IS8874A IS2920B (is) 2007-07-13 2010-01-27 Inflúensu veirulíkar agnir (VLPs) sem innihalda rauðkornakekki framleiddar í plöntu.
MA32604A MA31681B1 (fr) 2007-07-13 2010-02-08 Pseudo-particules du virus de la grippe (vlp) comprenant de l'hémagglutinine (ha) produit dans une plante.
ZA2010/00972A ZA201000972B (en) 2007-07-13 2010-02-10 Influenza virus-like particles (vlps) comprising hemagglutinin produces produced within a plant
IL206967A IL206967A (en) 2007-11-27 2010-07-13 Nucleic acid comprising a nucleotide sequence encoded for influenza virus hemoglutinin and a method for preparing the influenza virus-like particle comprising it
CR11612A CR11612A (es) 2007-11-27 2010-07-29 Particulas tipo virus de influenza recombinante (vlp) producidas en plantas transgenicas que expresan hemaglutinina
IS8919A IS2982B (is) 2007-11-27 2010-08-04 Raðbrigði inflúensuveitu-líkra agna (VLP) framleidd í erfðabreyttum plöntum sem tjá rauðkornakekk.
MA33088A MA32439B1 (fr) 2007-11-27 2010-08-13 Particules pseudovirales (vlp) de la grippe recombinées produites dans des plantes transgéniques exprimant l'hémagglutinine
ZA2010/05917A ZA201005917B (en) 2007-11-27 2010-08-19 Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
US13/734,886 US9452210B2 (en) 2007-07-13 2013-01-04 Influenza virus-like particles (VLPS) comprising hemagglutinin produced within a plant
US13/748,531 US9458470B2 (en) 2007-11-27 2013-01-23 Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin
HK13113472.5A HK1186207B (en) 2008-01-21 2013-12-04 Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
IL230708A IL230708A (en) 2007-07-13 2014-01-29 Influenza virus-like particles containing megalotinin produced in a plant
JP2014039035A JP5990207B2 (ja) 2007-11-27 2014-02-28 ヘマグルチニンを発現するトランスジェニック植物において産生された組換え型インフルエンザウイルス様粒子（ｖｌｐ）
JP2015231583A JP2016032477A (ja) 2007-11-27 2015-11-27 ヘマグルチニンを発現するトランスジェニック植物において産生された組換え型インフルエンザウイルス様粒子（ｖｌｐ）
US15/256,119 US10190132B2 (en) 2007-11-27 2016-09-02 Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin
US16/219,306 US11434497B2 (en) 2007-11-27 2018-12-13 Recombinant influenza virus-like particles (VLPS) produced in transgenic plants
US17/815,503 US20230044454A1 (en) 2007-07-13 2022-07-27 Recombinant influenza virus-like particles (vlps) produced in transgenic plants

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US95941407P 2007-07-13 2007-07-13
US60/959,414 2007-07-13
US99060307P 2007-11-27 2007-11-27
US60/990,603 2007-11-27
US1327207P 2007-12-12 2007-12-12
US61/013,272 2007-12-12

Publications (1)

Publication Number Publication Date
CA2615372A1 true CA2615372A1 (en) 2009-01-13

Family

ID=40255124

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002615372A Abandoned CA2615372A1 (en) 2007-07-13 2008-01-21 Influenza virus-like particles (vlps) comprising hemagglutinin
CA2693956A Active CA2693956C (en) 2007-07-13 2008-07-11 Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2693956A Active CA2693956C (en) 2007-07-13 2008-07-11 Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant

Country Status (19)

Country Link
US (4) US20100239610A1 (enExample)
EP (1) EP2173886B1 (enExample)
JP (1) JP5624465B2 (enExample)
KR (1) KR101541330B1 (enExample)
CN (1) CN101883856B (enExample)
AU (1) AU2008278222B2 (enExample)
CA (2) CA2615372A1 (enExample)
CR (1) CR11209A (enExample)
DK (1) DK2173886T3 (enExample)
EA (1) EA018206B1 (enExample)
ES (1) ES2428384T3 (enExample)
MX (1) MX2010000525A (enExample)
MY (1) MY155236A (enExample)
NZ (1) NZ582360A (enExample)
PL (1) PL2173886T3 (enExample)
PT (1) PT2173886E (enExample)
SI (1) SI2173886T1 (enExample)
TN (1) TN2009000557A1 (enExample)
WO (1) WO2009009876A1 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151159A2 (en) 2009-06-26 2010-12-29 Instytut Biochemii I Biofizyki Virus-like particle vector as a polyvalent platform for intracellular delivery of high-molecular-weight therapeutic substances, method for generating a virus like particle vector and use of a virus-like particle vector and a pharmaceutical composition containing said virus-like particle vector
US8771703B2 (en) 2008-07-08 2014-07-08 Medicago Inc. Soluble recombinant influenza antigens
US9452210B2 (en) 2007-07-13 2016-09-27 Medicago Inc. Influenza virus-like particles (VLPS) comprising hemagglutinin produced within a plant
US9458470B2 (en) 2007-11-27 2016-10-04 Medicago Inc. Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin
US9546375B2 (en) 2008-07-18 2017-01-17 Medicago Inc. Influenza virus immunizing epitope
US9815873B2 (en) 2011-03-23 2017-11-14 Medicago Inc. Method for recovering plant-derived proteins
US10272148B2 (en) 2009-06-24 2019-04-30 Medicago Inc. Chimeric influenza virus-like particles comprising hemagglutinin
US11826419B2 (en) 2009-09-22 2023-11-28 Medicago Inc. Method of preparing plant-derived VLPs

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324181B (en) 2001-04-16 2010-05-01 Martek Biosciences Corp Product and process for transformation of thraustochytriales microorganisms
WO2005018539A2 (en) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
ES2527503T3 (es) 2005-03-08 2015-01-26 Medimmune, Llc Virus influenza reordenantes
JP5683811B2 (ja) * 2006-07-27 2015-03-11 タケダ ヴァクシーンズ， インコーポレイテッド キメラインフルエンザウイルス様粒子
RU2523587C2 (ru) * 2008-07-11 2014-07-20 МЕДИММЬЮН, ЭлЭлСи Варианты гемагглютинина и нейрамидазы вируса гриппа
AU2015202195B2 (en) * 2008-07-18 2017-10-12 Medicago Inc. New influenza virus immunizing epitope
TWI504749B (zh) 2009-03-16 2015-10-21 Dsm Ip Assets Bv 於網黏菌門微生物中生產蛋白質之技術
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
US8933200B2 (en) 2009-04-09 2015-01-13 Alfa Biogene International B.V. Filtration of a liquid comprising a plant stress protein
AU2010266129B2 (en) 2009-07-02 2016-04-14 Massachusetts Institute Of Technology Compositions and methods for diagnosing and/or treating influenza infection
IN2012DN06277A (enExample) * 2009-12-28 2015-09-25 Dsm Ip Assets Bv
AR079767A1 (es) * 2009-12-28 2012-02-15 Merial Ltd Antigeno ndv (virus de la enfermedad de newcastle) recombinante y usos del mismo
EP2519636B8 (en) 2009-12-28 2017-08-09 DSM IP Assets B.V. Production of hemagglutinin-neuraminidase protein in microalgae
AU2015202267B2 (en) * 2010-01-26 2017-03-23 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
US9701723B2 (en) 2010-02-18 2017-07-11 Icahn School Of Medicine At Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
MX2012011300A (es) 2010-03-30 2012-11-29 Sinai School Medicine Vacunas del virus de influenza y usos de las mismas.
CA2811023A1 (en) 2010-09-21 2012-03-29 Massachusetts Institute Of Technology Influenza treatment and/or characterization; human-adapted ha polypeptides; vaccines
MX2013003451A (es) 2010-09-30 2013-09-02 Franvax S R L Generacion de particulas de virosoma.
WO2012047941A2 (en) 2010-10-04 2012-04-12 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
EP2632562B1 (en) * 2010-10-27 2020-08-05 Philip Morris Products S.a.s. Methods for capturing virus like particles from plants using expanded bed chromatography
ES2614527T3 (es) 2010-11-04 2017-05-31 Medicago Inc. Sistema de expresión en plantas
TWI526539B (zh) * 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
EP2665817A1 (en) * 2011-01-17 2013-11-27 Philip Morris Products S.a.s. Vectors for nucleic acid expression in plants
US20140227322A1 (en) * 2011-06-13 2014-08-14 Medicago Inc. Rabies virus like particle production in plants
JP6113155B2 (ja) 2011-06-20 2017-04-12 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原
HK1200102A1 (en) 2011-09-20 2015-07-31 西奈山医学院 Influenza virus vaccines and uses thereof
US11390878B2 (en) 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
TWI700368B (zh) 2011-09-30 2020-08-01 苜蓿股份有限公司 增加植物類病毒顆粒產率
WO2013068593A1 (en) * 2011-11-11 2013-05-16 Philip Morris Products S.A. Influenza virus -like particles (vlps) comprising hemagglutinin produced nicotiana tabacum
US9234008B2 (en) 2012-02-07 2016-01-12 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for H3N2, H2N2, and B influenza viruses
US9566327B2 (en) 2012-02-13 2017-02-14 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for human and avian H5N1 influenza
US9364530B2 (en) 2012-03-22 2016-06-14 Fraunhofer Usa, Inc. Virus-like particles comprising a matrix protein from a plant enveloped virus and uses thereof
PL3597757T3 (pl) * 2012-05-11 2021-05-31 Medicago Inc. Wytwarzanie cząstek podobnych do rotawirusów w roślinach
AU2013312971B2 (en) * 2012-09-05 2019-04-18 Medicago Inc. Picornavirus-like particle production in plants
NZ627796A (en) 2012-12-18 2017-07-28 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
JP2016516415A (ja) * 2013-03-28 2016-06-09 メディカゴ インコーポレイテッド 植物におけるインフルエンザウイルス様粒子の生成
US12467058B2 (en) 2013-03-28 2025-11-11 Aramis Biotechnologies Inc. Influenza virus-like particle production in plants
WO2015034042A1 (ja) 2013-09-06 2015-03-12 三菱化学株式会社 植物を用いたタンパク質の製造方法
AU2015234595B2 (en) 2014-03-27 2021-03-25 Medicago Inc. Modified CPMV enhancer elements
WO2016004536A1 (en) 2014-07-11 2016-01-14 Medicago Inc. Modifying protein production in plants
HK1245333A1 (zh) 2015-01-23 2018-08-24 Medicago Inc. 在植物中产生轮状病毒样颗粒
EP3247389A4 (en) 2015-01-23 2019-10-30 Icahn School of Medicine at Mount Sinai INFLUENZAVIRUSSCHUTZIMPFPLÄNE
KR101637955B1 (ko) * 2015-05-18 2016-07-08 한국생명공학연구원 범용성 인플루엔자 바이러스 백신 조성물
RU2728472C2 (ru) 2015-07-02 2020-07-29 Медикаго Инк. Активатор сигнального пути жасмоновой кислоты
MX2018015755A (es) 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
JP7423875B6 (ja) 2018-03-14 2024-03-15 メディカゴ インコーポレイテッド 植物発現エンハンサ
KR101964044B1 (ko) * 2018-03-14 2019-04-02 인제대학교 산학협력단 재조합 아데노바이러스를 이용한 다가형 인플루엔자 생백신 플랫폼
US12364746B2 (en) 2018-06-21 2025-07-22 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
AU2019295495B2 (en) 2018-06-27 2025-05-22 Aramis Biotechnologies Inc. Influenza virus hemagglutinin mutants
CA3104392A1 (en) * 2018-07-04 2020-01-09 Probiogen Ag Method for purifying an enveloped virus
BR112021017899A2 (pt) 2019-03-14 2021-12-21 Medicago Inc Intensificador de expressão vegetal endógeno
CA3137160A1 (en) 2019-04-24 2020-10-29 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
CA3145200A1 (en) 2019-07-03 2021-01-07 Aillis Inc. Pharmaceutical composition for treating influenza virus infections
CN111122417B (zh) * 2020-02-22 2022-06-21 太原理工大学 一种测定含瓦斯煤开闭孔总体积膨胀率的装置及方法
EP4351320A1 (en) 2021-06-09 2024-04-17 ImmunityBio, Inc. Methods and systems for producing a protein of interest in a plant
CN115992101B (zh) * 2023-03-22 2023-07-28 深圳市卫光生物制品股份有限公司 一种流感病毒裂解疫苗原液的制备方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0203177A4 (en) 1984-11-29 1987-04-28 Scripps Clinic Res POLYPEPTIDES AND ANTIBODIES ASSOCIATED WITH VIRAL GLUCOPROTEINS WITHOUT GLUCOSE.
US5232833A (en) * 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
ATE142883T1 (de) * 1991-03-28 1996-10-15 Rooperol Na Nv Zusammensetzungen von phytosterolen mit phytosterolinen als immunmodulatoren
US6326470B1 (en) 1997-04-15 2001-12-04 The Penn State Research Foundation Enhancement of accessibility of cellulose by expansins
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
GB9414118D0 (en) 1994-07-13 1994-08-31 Axis Genetics Ltd Modified plant viruses as vectors of heterologous peptides
US6020169A (en) 1995-07-20 2000-02-01 Washington State University Research Foundation Production of secreted foreign polypeptides in plant cell culture
US6042832A (en) 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
US20010006950A1 (en) 1998-02-11 2001-07-05 Juha Punnonen Genetic vaccine vector engineering
US6489537B1 (en) 1998-08-07 2002-12-03 The Trustees Of The University Of Pennsylvania Phytochelatin synthases and uses therefor
MXPA01001445A (es) 1998-08-11 2002-11-29 Large Scale Biology Corp Metodo para recuperar proteinas a partir del fluido intersticial de tejidos de plantas.
US6392121B1 (en) 1998-10-07 2002-05-21 Boyce Thompson Institute For Plant Research Gemini virus vectors for gene expression in plants
US6287570B1 (en) * 1998-11-23 2001-09-11 Patricia L. Foley Vaccine against swine influenza virus
FR2791358B1 (fr) 1999-03-22 2003-05-16 Meristem Therapeutics Promoteurs chimeriques d'expression, cassettes d'expression, plasmides, vecteurs, plantes et semences transgeniques les contenant et leurs methodes d'obtention
ES2262514T3 (es) 1999-04-29 2006-12-01 Syngenta Limited Plantas resistentes a herbicidas.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US7449188B2 (en) 2001-01-18 2008-11-11 Vlaams Interuniversitair Instituut Voor Biotechnologie Recombinant oligometric protein complexes with enhanced immunogenic potential
CN1333370A (zh) * 2001-08-16 2002-01-30 深圳市三方圆信息技术有限公司 抗家禽病毒病的作物及其生产方法
AU2003219745B8 (en) * 2002-02-13 2008-10-09 Wisconsin Alumni Research Foundation Signal for packaging of influenza virus vectors
US7041500B2 (en) 2002-02-14 2006-05-09 Novavax, Inc. Insect cell line
EP2319935B1 (en) * 2002-03-19 2016-04-27 Stichting Dienst Landbouwkundig Onderzoek GnTIII (UDP-N-acetylglucosamine:Beta -D mannoside Beta (1,4)-N-acetylglucosaminyltransferase III) expression in plants.
ES2224792B1 (es) 2002-06-28 2007-02-16 Era Plantech, S.L. Produccion de peptidos y proteinas por acumulacion de cuerpos proteicos derivados de reticulos endoplasmico en plantas.
CU23202A1 (es) * 2003-01-31 2007-05-18 Ct Ingenieria Genetica Biotech ANTIGENOS RECOMBINANTES DEL VIRUS DE LA HEPATITIS A OBTENIDOS EN CéLULAS VEGETALES
CN1460718A (zh) * 2003-04-11 2003-12-10 浙江大学 表达传染性支气管炎病毒纤突蛋白的转基因马铃薯生产方法
NZ542933A (en) 2003-05-05 2009-08-28 Dow Agrosciences Llc Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production
AU2004235813B2 (en) * 2003-05-05 2010-07-29 Boyce Thompson Institute For Plant Research Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
WO2005018539A2 (en) * 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
CN1926238A (zh) * 2004-02-27 2007-03-07 陶氏化学公司 植物细胞中的高效肽生产
WO2006016380A2 (en) 2004-08-13 2006-02-16 Council Of Scientific And Industrial Research A chimeric g protein based rabies vaccine
ES2662118T3 (es) 2005-04-29 2018-04-05 University Of Cape Town Expresión de proteínas virales en las plantas
CN100410378C (zh) 2005-05-09 2008-08-13 中国农业科学院生物技术研究所 编码禽流感血凝素的基因及其植物表达载体和应用
CA2615658A1 (en) 2005-07-19 2007-01-25 Dow Global Technolgies Inc. Recombinant flu vaccines
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
EP1945250A4 (en) 2005-08-16 2010-05-19 Hawaii Biotech Inc RECOMBINANT SUBUNIT VACCINE AGAINST INFLUENZA
RU2483751C2 (ru) * 2005-10-18 2013-06-10 Новавакс, Инк. ФУНКЦИОНАЛЬНЫЕ ВИРУСОПОДОБНЫЕ ЧАСТИЦЫ ГРИППА (VLPs)
AU2006335256B2 (en) 2005-11-22 2012-10-18 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
EP1984405A4 (en) 2006-02-13 2010-06-30 Fraunhofer Usa Inc INFLUENZA ANTIGENES, VACCINE COMPOSITIONS AND RELATED METHODS
KR20080109094A (ko) 2006-04-21 2008-12-16 다우 아그로사이언시즈 엘엘씨 조류 인플루엔자 백신 및 이용방법
US8778353B2 (en) 2006-05-01 2014-07-15 Technovax, Inc. Influenza virus-like particle (VLP) compositions
WO2008054540A2 (en) 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
US20070286873A1 (en) * 2006-05-23 2007-12-13 Williams John V Recombinant Influenza H5 Hemagluttinin Protein And Nucleic Acid Coding Therefor
US7730950B2 (en) 2007-01-19 2010-06-08 Halliburton Energy Services, Inc. Methods for treating intervals of a subterranean formation having variable permeability
CN104962579A (zh) 2007-06-15 2015-10-07 麦迪卡格公司 修饰植物中的糖蛋白产生
KR100964462B1 (ko) 2007-07-10 2010-06-16 성균관대학교산학협력단 형질전환 식물 유래의 조류독감 바이러스 백신 및 그 제조방법
CA2615372A1 (en) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
CA2696764A1 (en) 2007-08-20 2009-02-26 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
NZ587108A (en) * 2007-11-27 2013-04-26 Medicago Inc Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
CN101909454A (zh) 2007-12-28 2010-12-08 荷兰联合利华有限公司 从茶回收香味化合物的方法
GB0800272D0 (en) 2008-01-08 2008-02-13 Plant Bioscience Ltd Protein expression systems
SG187500A1 (en) 2008-01-21 2013-02-28 Medicago Inc Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
DK2294202T3 (en) 2008-07-08 2015-08-31 Medicago Inc SOLUBLE RECOMBINANT INFLUENZA ANTIGENES
KR101745925B1 (ko) 2008-07-18 2017-06-12 메디카고 인코포레이티드 신규 인플루엔자 바이러스 면역화 에피토프
CA2736796A1 (en) 2008-08-27 2010-03-04 Arizona Board Of Regents For And On Behalf Of Arizona State University A dna replicon system for high-level rapid production of vaccines and monoclonal antibody therapeutics in plants
WO2010025235A1 (en) 2008-08-29 2010-03-04 Regents Of The University Of Michigan Selective ligands for the dopamine 3 (d3) receptor and methods of using the same
WO2010077712A1 (en) 2008-12-09 2010-07-08 Novavax, Inc. Bovine respiratory syncytial virus virus-like particle (vlps)
SI2445928T1 (en) * 2009-06-24 2018-05-31 Medicago Inc. HYPER PARTICULARS, SIMILAR VIRUSES OF GRIPE, WHICH HAVE EXPOSED HEMAGLUTININE
WO2011011390A1 (en) 2009-07-20 2011-01-27 Novavax, Inc. Purified recombinant influenza virus ha proteins
SG178918A1 (en) 2009-09-22 2012-04-27 Medicago Inc Method of preparing plant-derived vlps
CA2789945A1 (en) 2010-02-18 2011-08-25 Technovax, Inc. Universal virus-like particle (vlp) influenza vaccines
ES2614527T3 (es) 2010-11-04 2017-05-31 Medicago Inc. Sistema de expresión en plantas
CA2817005C (en) 2010-11-05 2018-09-11 Novavax Inc. Rabies glycoprotein virus-like particles (vlps)
TWI526539B (zh) 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9452210B2 (en) 2007-07-13 2016-09-27 Medicago Inc. Influenza virus-like particles (VLPS) comprising hemagglutinin produced within a plant
US9492528B2 (en) 2007-07-13 2016-11-15 Medicago Inc. Influenza virus-like particles (VLPS) comprising hemagglutinin
US9458470B2 (en) 2007-11-27 2016-10-04 Medicago Inc. Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin
US10190132B2 (en) 2007-11-27 2019-01-29 Medicago Inc. Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin
US11434497B2 (en) 2007-11-27 2022-09-06 Medicago Inc. Recombinant influenza virus-like particles (VLPS) produced in transgenic plants
US8771703B2 (en) 2008-07-08 2014-07-08 Medicago Inc. Soluble recombinant influenza antigens
US9546375B2 (en) 2008-07-18 2017-01-17 Medicago Inc. Influenza virus immunizing epitope
US10272148B2 (en) 2009-06-24 2019-04-30 Medicago Inc. Chimeric influenza virus-like particles comprising hemagglutinin
WO2010151159A2 (en) 2009-06-26 2010-12-29 Instytut Biochemii I Biofizyki Virus-like particle vector as a polyvalent platform for intracellular delivery of high-molecular-weight therapeutic substances, method for generating a virus like particle vector and use of a virus-like particle vector and a pharmaceutical composition containing said virus-like particle vector
US11826419B2 (en) 2009-09-22 2023-11-28 Medicago Inc. Method of preparing plant-derived VLPs
US11833200B2 (en) 2009-09-22 2023-12-05 Medicago Inc. Method of preparing plant-derived proteins
US9815873B2 (en) 2011-03-23 2017-11-14 Medicago Inc. Method for recovering plant-derived proteins
CN110041397A (zh) * 2011-03-23 2019-07-23 麦迪卡格公司 回收植物来源的蛋白质的方法

Also Published As

Publication number Publication date
US20230044454A1 (en) 2023-02-09
US9452210B2 (en) 2016-09-27
CN101883856A (zh) 2010-11-10
PT2173886E (pt) 2013-09-03
CR11209A (es) 2010-03-23
US20130183341A1 (en) 2013-07-18
CA2693956C (en) 2013-09-24
KR20100032920A (ko) 2010-03-26
EP2173886B1 (en) 2013-06-26
SI2173886T1 (sl) 2013-11-29
EA201000195A1 (ru) 2010-10-29
CA2693956A1 (en) 2009-01-22
MX2010000525A (es) 2010-04-27
KR101541330B1 (ko) 2015-08-05
DK2173886T3 (da) 2013-09-30
TN2009000557A1 (en) 2011-03-31
PL2173886T3 (pl) 2013-12-31
AU2008278222B2 (en) 2014-03-06
WO2009009876A1 (en) 2009-01-22
EP2173886A1 (en) 2010-04-14
EA018206B1 (ru) 2013-06-28
NZ582360A (en) 2012-04-27
CN101883856B (zh) 2013-10-30
AU2008278222A1 (en) 2009-01-22
EP2173886A4 (en) 2010-10-13
JP2010533001A (ja) 2010-10-21
US20100239610A1 (en) 2010-09-23
MY155236A (en) 2015-09-30
ES2428384T3 (es) 2013-11-07
JP5624465B2 (ja) 2014-11-12
US9492528B2 (en) 2016-11-15
US20110293650A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
US20230044454A1 (en) Recombinant influenza virus-like particles (vlps) produced in transgenic plants
US11434497B2 (en) Recombinant influenza virus-like particles (VLPS) produced in transgenic plants
EP2570484B1 (en) Influenza virus-like particles (VLPS) comprising hemagglutinin
EP2318530A1 (en) New influenza virus immunizing epitope
IL203018A (en) Influenza virus-like particles containing megalotinin produced in a plant
HK1142627B (en) Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant
HK1186207B (en) Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
HK1183324A (en) Influenza virus-like particles (vlps) comprising hemagglutinin

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150121